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Abstract There is a wide choice of fecal occult blood
tests (FOBTs) for colorectal cancer screening. Goal: To
highlight the issues applicable when choosing a FOBT, in
particular which FOBT is best suited to the range of
screening scenarios. Four scenarios characterize the con-
straints and expectations of screening programs: (1) limited
colonoscopy resource with a need to constrain test positivity
rate; (2) a priority for maximum colorectal neoplasia
detection with little need to constrain colonoscopy work-
load; (3) an ‘‘adequate’’ endoscopy resource that allows
balancing the benefits of detection with the burden of
service provision; and (4) a need to maximize participation
in screening. Guaiac-based FOBTs (gFOBTs) have signif-
icant deficiencies, and fecal immunochemical tests (FITs)
for hemoglobin have emerged as better tests. gFOBTs are
not sensitive to small bleeds, specificity can be affected by
diet or drugs, participant acceptance can be low, laboratory
quality control opportunities are limited, and they have a
fixed hemoglobin concentration cutoff determining posi-
tivity. FITs are analytically more specific, capable of
quantitation and hence provide flexibility to adjust cutoff
concentration for positivity and the balance between
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sensitivity and specificity. FITs are clinically more sensitive
for cancers and advanced adenomas, and because they are
easier to use, acceptance rates are high. Conclusions: FOBT
must be chosen carefully to meet the needs of the applicable
screening scenario. Quantitative FIT can be adjusted to suit
Scenarios 1, 2 and 3, and for each, they are the test of
choice. FITs are superior to gFOBT for Scenario 4 and
gFOBT is only suitable for Scenario 1.
Keywords Colorectal cancer  Screening  Fecal occult
blood test  FIT  Sensitivity  Specificity
Introduction
The Basis of Effective Screening Tests
Colorectal cancer (CRC) screening reduces CRC-related
mortality and potentially CRC incidence depending on the
method used [1–6]. The former is achieved by earlier
detection at more readily cured stages, while the latter is
achieved by removal of adenomas (i.e., pre-invasive dys-
plastic lesions).
Screening methods using endoscopic visualization as the
primary screening modality have proved effective with
flexible sigmoidoscopy (FS) being supported by population
randomized controlled trials (RCTs) [5–7] and colonos-
copy by cohort and case–control studies [8, 9]. The bio-
logical basis for the prevention and early detection of CRC
for these tests is the endoscopic visualization and removal
of a neoplastic lesion. Detection of the presence of
hemoglobin in feces using a fecal occult blood test (FOBT)
has also proved effective; guaiac-based FOBTs (gFOBTs)
are proven by multiple RCTs [1–4] and the newer tech-
nology, fecal immunochemical tests (FITs) for hemoglo-
bin, by studies in CRC cases and controls [10–12]. The
biological basis for both depends on the neoplastic lesion
having a bleeding phenotype.
Screening by visualization of a neoplastic lesion or by
FOBT is advocated by many screening guidelines that are
based on the strength of published evidence. The differences
between endoscopic and the less-invasive FOBT screening
have important implications for population participation.
The goals of this opinion piece are to highlight the
issues to consider when choosing a FOBT for screening
and to address several key challenges and controversies.
The Goals and Nature of a Screening Program
Screening aims to reduce CRC mortality and incidence on a
population basis. The International Agency for Research on
Cancer (IARC) states that screening programs, whether
organized or opportunistic, should provide protection
against the harms of screening, over-screening, the compli-
cations of screening, poor follow-up of those who test
positive and poor quality of treatment [13]. We add to this
list the need for screening tests to be of proven efficacy and
of high analytical quality.
A screening test is just one event in a multi-step process
that includes engagement, testing, diagnostic confirmation,
communication, treatment and rescreening or surveillance as
necessary [14]. While the test must possess the requisite
sensitivity and specificity, individuals must also be willing to
do the test (acceptance is a characteristic of the test itself) and
healthcare professional involvement must be of high quality.
Full colonoscopy can be used for primary, one-step
screening. Simpler tests such as FOBT provide the option
of two-step screening, where the test selects participants at
a higher risk of cancer who can then proceed to diagnostic
investigation by colonoscopy. The change in the likelihood
of cancer detection for these two methods can be simply
calculated as sensitivity divided by 1 - specificity [15,
16]. In the gFOBT RCTs, the likelihood of finding a cancer
given a positive test was eightfold to 25-fold times greater
relative to colonoscopy without any intervening test [17].
Thus, it is crucial that test-positive individuals are sub-
jected to diagnostic clarification.
Willingness to undertake the screening test is the first
crucial step. In many screening settings, only a minority of
the eligible population actually participates. For simple
tests with low application sensitivity (one screen only),
repeated participation is necessary. An example of how
participation can determine the effectiveness of screening
was shown by first-round screening in a Spanish trial
comparing colonoscopy with FIT [18]. With participation
of 34 % with FIT and 25 % with colonoscopy, and the
willingness by some in the latter group to be first screened
with FIT, the number of CRCs detected was higher in those
Fig. 1 Key steps in screening, each of which needs to be completed
with high quality for there to be an impact on mortality from and/or
incidence of CRC
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who were first screened by FIT. The importance of repe-
ated screening is demonstrated in the gFOBT RCTs where
it was documented that some CRCs were only detected in
subsequent rounds [3, 4], possibly due to intermittent
bleeding from important lesions or the poor analytical
sensitivity of gFOBT. Although first-round FIT screening
detects more cancers, repeated screening is also necessary
[19]. Of course, rapid development of new lesions might
also occur.
The key steps in screening are shown in Fig. 1.
The Evidence for Guaiac-Based FOBT (gFOBT)
The earliest technology for FOBT, namely gFOBT, can be
seen as simple and of proven benefit, but it has poor
accuracy and subject (screenee) acceptance. gFOBTs also
lack precise objective end points. We provide an overview
of issues that have stimulated a quest for a better-per-
forming FOBT.
Performance of gFOBT
The effect of gFOBT on mortality is modest. The tra-
ditional (i.e., unrehydrated) gFOBT (Hemoccult II was
the FOBT used) returned an intention-to-screen reduction
in CRC mortality of 15 % [20]. This effect was limited
by screenee acceptance (generally just over one-half of
the population) and sensitivity for neoplasia. Once-only
test sensitivity for cancer may approximate 50 % [21]
although other studies indicate it is lower [22]. For some
countries, this limited sensitivity raised concern among
practitioners for legal liability for missed lesions. In
consequence, some jurisdictions have not been enthusi-
astic about adopting this as the primary population
screening.
Hydration of gFOBT samples improves the detection of
heme. This can lead to larger CRC mortality reduction [1],
but also activates plant peroxidases and so compromises
specificity [23]. This led to the development of more sen-
sitive gFOBT, sometimes referred to as ‘‘high-sensitivity
gFOBT.’’ An early example is Hemoccult Sensa—its
cancer sensitivity has been shown to be twice that of
Hemoccult II [22]. However, poor specificity is a problem
with sensitive gFOBT [22, 24], and their use is associated
with high colonoscopy demands. The optimal dietary
restrictions to minimize false positives with gFOBT are
well known [17]. However, these restrictions are barriers to
participation [25]. In certain populations, e.g., Asian set-
tings, the false-positive rate with more sensitive gFOBT is
high, possibly due to dietary interference [22, 24] which
renders them relatively useless in such settings.
Technical Issues with gFOBT
gFOBT detection of blood is dependent on heme in feces
[26]. When hydrogen peroxide is added during analysis,
heme reacts with the hydrogen peroxide developer to oxi-
dize guaiac, resulting in a color change to blue. While
gFOBTs are cheap and designed as point-of-care tests, they
require a moderate quantity of heme to effect a visible
change in color and thus are not analytically very sensitive
to the presence of blood [27]. The method relies on simple
oxidation, and therefore, any dietary peroxidases, such as
heme from myoglobin in red meat, peroxidase in plants,
etc., or antioxidant, such as vitamin C, have the potential to
confound the result. The gFOBT is therefore an inherently
nonspecific test.
gFOBTs are technically crude, and in the age of quality
assurance of diagnostic tests, they fall far short of what
would be ideal for a test that might be analyzed in the high
volumes usual in programmatic screening [28]. A major
issue is that gFOBTs have a subjective and evanescent end
point not readable, let alone quantifiable, using automated
instrumentation and therefore not suited to high-throughput
screening programs. Professional quality assurance pro-
grams are minimal [29], and problems in variation in
reading of gFOBT among laboratory staff have been well
known for decades [30, 31].
Technological Advances in Detection of Hemoglobin
in Feces
It is not surprising, therefore, that advances in methods to
detect and measure hemoglobin in feces have been welcomed
[32]. An understanding of the biochemical fate of hemoglo-
bin in the intestinal lumen provides a basis for understanding
the advantages of these new technologies [26].
Biochemical Fate of Hemoglobin in the Gut
Hemoglobin is digested/degraded in different ways in dif-
ferent regions in the gut. In the stomach and small intestine,
the globin moiety is digested by proteolytic enzymes of
endogenous origin. Proteolysis also proceeds in the colon
but at a slower and highly variable rate and partly due to
microbial enzymes [26]. Such changes have different
implications for the technologies employed in detection
depending on whether they target the heme or globin
moieties.
In the colon, heme is subject to bacterial enzymatic
degradation which releases iron and protoporphyrins
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[33]—the resultant products have no peroxidase activity
and so gFOBT detectability is lost.
Consequently, feces will contain a mix of intact hemo-
globin, intact heme and globin as well as globin and heme
in varying stages of degradation the degree to which will
depend on the location of bleeding in the gut.
Technology that Detects These Products
While gFOBT positivity is dependent on the presence of
the heme, more recent diagnostic tests target other moieties
or derivatives of hemoglobin.
Fecal Immunochemical Tests (FITs) for Hemoglobin
‘‘FIT’’ was recommended as the preferred name for this
screening technology by a World Endoscopy Organization
(WEO) Expert Working Group in 2012 [34] to avoid
confusion with gFOBTs and to emphasize the substantial
analytical, clinical and organizational opportunities these
tests provide for CRC screening.
At a technical level, FITs use antibodies, monoclonal or
polyclonal, specific for the globin moiety of human
hemoglobin. A variety of immunoassay methods, including
immunochromatography, immunoturbidimetry and ELISA,
measure the development of antibody–globin complexes
[35]. Generally, the technique is analytically sensitive to
low concentrations of globin and is not known to be subject
to direct interference from other constituents of feces
including medication and dietary products.
The immunoassay methods are not all the same and
differ substantially between qualitative and quantitative
FIT [36]. FIT can be placed into two general analytical
techniques: lateral flow immunochromatographic analysis
typically exploited in point-of-care (POC) devices and
laboratory instrument-based immunoturbidimetry or alter-
native end point analyses [35]. Many qualitative FIT
(positive/negative result) devices are available and are
designed for use at the point-of-care, outside of a labora-
tory [35]. For qualitative tests, only the manufacturer can
adjust the conditions of the analysis and hence the sensi-
tivity for detecting globin; they are generally not adjustable
by the end user. Even though they are point-of-care tests, in
application they require skill and practice to obtain con-
sistency in sample application and visual interpretation.
Experience with a range of POC devices in a primary care-
led screening program in the Czech Republic has recently
shown widely different positivity rates and an inability to
monitor analytical performance across the program. Few, if
any, of the POC FIT have peer-reviewed published results
of their performance characteristics or laboratory quality
control in large average-risk populations.
Quantitative FITs generally use immunoturbidimetric
analysis and so provide a semiquantitative measure of
globin in feces captured in a buffer solution in the sampling
device. While the measured concentration is, in part,
dependent on the amount of feces sampled, studies have
consistently shown that the concentration is related to the
nature of the neoplastic pathology present [37–39]. In other
words, the degree of bleeding discriminates between nor-
mal physiological gastrointestinal bleeding and the pre-
sence and extent of neoplasia-related bleeding. The
criterion value (the value used to set positivity, here a
hemoglobin concentration in feces and hereafter referred to
as the cutoff concentration) for discrimination can be
readily adjusted with a quantitative test [37–39]. By
adjusting the cutoff, the performance can be adjusted to
match the desired sensitivity and specificity of a screening
activity [40]. This is illustrated in Fig. 2.
With quantitative FIT, one can set the cutoff concentra-
tion to a desired sensitivity or specificity or to manage
colonoscopy follow-up rates according to the operational
imperatives of a screening program. This brings both prac-
tical and clinical advantages to population screening. It
enables clinical interpretation of the result and its signifi-
cance in a manner similar to the interpretation of a choles-
terol or glucose measurement result against the risk of
associated disease. It also raises the possibility of generating
a multivariate risk score, incorporating other accessible risk
factors such as age, sex, family history, screening history,
and perhaps BMI and smoking [41]. Quantitative FIT opens
opportunities for major enhancement to the current binary
risk (positive or negative) outcome offered by gFOBT and is
an approach that has been described by Stegeman et al. [42].
FITs, especially the quantitative versions, also provide
major laboratory advantages over gFOBT. The end point is
more objective, easier to read (often by an instrument) and
more amenable to quality assurance (QA) procedures. FIT
can be partly or fully automated and is therefore well suited
to large-scale population-based screening programs.
FITs are analytically more specific than gFOBT and not
subject to the factors known to interfere with gFOBT [17].
They are also selective for colorectal bleeding since globin
from the upper gastrointestinal tract is degraded readily by
digestive proteolytic enzymes, with a study showing that up to
100 mL of ingested blood was not detected by some immu-
nochemical methods but was by gFOBT [26]. FIT is, however,
not clinically specific because nonneoplastic and benign
pathologies may also bleed and there is a baseline level of
globin in feces that reflects physiological blood loss [39].
612 Dig Dis Sci (2015) 60:609–622
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Heme-Derived Porphyrin Assay
A heme–porphyrin assay (HemoQuant) has been developed
to measure fecal heme and heme-derived porphyrins [43],
but it has not proved useful for screening. Like gFOBT, it
is subject to the effects of red meat ingestion [33] and it
would detect heme in shed cells (e.g., in cytochromes) and
in ingested foods.
Choosing a FOBT for the Screening Context
Choosing the right FOBT for a given screening setting
requires consideration of the attributes of the two main
technological options—FIT and gFOBT. There is a range
of apparently similar products for each technology [35], but
each will have different characteristics due to assay design,
choice of antibody (for FIT), source and concentration of
guaiac (for gFOBT) and volume/mass of sample collected
in, or applied to, the device. Two products might use the
same technology—gFOBT or FIT—but might have very
different performance characteristics. When choosing a test
technology, consideration must also be given to how the
test will be applied in the screening program (e.g., target
population, climate, number of test samples, cutoff con-
centration and testing frequency).
Consideration of test operating characteristics and
required accuracy are crucial since these relate to the
likelihood that neoplasia is present and also to the health
system demands and to the derived cost benefits.
Informative test operating characteristics [44] fall into
two main categories of program consequence reflecting the
test capacity to detect neoplasia (related to sensitivity) and
the burden on the health system associated with detection
(related to specificity). Table 1 shows both direct and
practical measures of accuracy (test operating characteris-
tics) which are used for ROC (receiver operating charac-
teristic) analysis. From the discussion in Sect. 2.2.1 and
Fig. 2, it is apparent that sensitivity cannot be adjusted
independently of specificity.
Consideration of the many 2-step centrally coordinated
screening programs around the world [45] shows that dif-
ferent health systems vary in their focus on which strategic
outcome is most important in designing the screening
program. The choice of FOBT should suit the requirements
of the program. In simple terms, one needs to decide on the
desired balance between detection and the effort involved
in detection as well as the desired degree of population
engagement. Consideration of four main strategic scenarios
facilitates the selection of an FOBT:
1. Highly constrained colonoscopy resources: The colon-
oscopy workload created by screening which is
determined by the test positivity rate in the screening
population. Some health care systems consider it
necessary to constrain positivity to around 2–3 %.
This achieves efficient detection with a small number
Fig. 2 Theoretical representation of distribution of fecal hemoglobin
concentrations in normal subjects and cancer cases. The arrows
labeled a, b and c point to different fecal hemoglobin concentrations
(criterion values) which might be chosen to discrimination between
those without pathology (normal) and those with cancer. At c, most
normals are declared negative (hence a high specificity) and a
majority but not all cancers are declared positive, while at a, most
cancers are included (high sensitivity) but more normals will test
positive
Table 1 Relationship between
direct, practical measures
(operating characteristics) of a
screening test result, how each
informs assessment of test
accuracy and what the
consequence of the result is for
a screening program
Test
result
Result of diagnostic
verification
Operating
characteristic
Related accuracy
characteristic
Program consequence
Positive True, hence true
positive (TP)
True-positive
rate (TPR)
Sensitivity; TP/(TP ? FN) Detection of
neoplasia
Positive predictive value;
TP/(TP ? FP)
Efficiency of
detection
False, hence false
positive (FP)
False-positive
rate (FPR)
Specificity; 1 – FPR Burden associated
with detection
Negative True, hence true
negative (TN)
Specificity; TN/
(TN ? FP)
Exclusion of
neoplasia
False, hence false
negative (FN)
Missed lesion Missed cancer
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needed to colonoscope to detect one cancer but means
that a significant number of cancers and advanced
adenomas are missed, leading to a high interval cancer
rate. This may in part be addressed by accepting a short
screening interval, but this obviously translates in time
to higher colonoscopy demands.
2. Maximum detection: Maximization of detection of
cancer and adenomas means applying the most sensi-
tive FOBT with less concern for specificity. This
approach is more common in screening settings where
screening is promoted but not centrally organized. It
has led to the introduction of the term ‘‘high-sensitiv-
ity’’ FOBT and specifically refers to those FOBT that
return a once-only test sensitivity for cancer of above
50 % [46].
3. Balancing detection and colonoscopy burden: Com-
promising between maximizing detection and colon-
oscopy burden by screening with higher-sensitivity
FOBT that does not create a large colonoscopy
demand. This is equivalent to choosing an optimal
PPV for a given screening setting.
4. Optimal screening participation, whether offering
FOBT as the only screening modality, or in a multi-
modality program: Population detection is the product
of participation rate and test sensitivity so it is crucial
to detection of neoplasia. Screening environments vary
in the emphasis placed on this crucial parameter, but it
applies to some degree in each of the above scenarios.
Of course, rather than be offered as part of a centrally
coordinated screening program, screening might be offered
to an individual in the setting of a face-to-face consultation.
Here, tailoring the screening test to the individual’s situa-
tion with attention to test quality, effectiveness and cost is
important [35]. Scenario 3 provides this flexibility in that it
allows for choosing from a range of test performance
characteristics.
The question therefore arises as to which type of FOBT
is suited to each of these four scenarios?
Comparative Performance of FOBT
Before describing how different FOBT might be selected to
suit these scenarios, it is useful to summarize what is
known about the operating characteristics and accuracy of
the different FOBTs. This would be most thoroughly
informed by large, comparative screening studies, but such
studies are impracticable. Consequently, we plot sensitivity
and specificity for cancer reported for gFOBT (Fig. 3) [47–
58] and FIT (Fig. 4) [38, 39, 48, 54, 55, 59–66] from a
range of studies, to provide some idea of the range of
sensitivity/specificity relationships for these technologies.
It will be obvious that these measures of accuracy vary
greatly between tests within a technology as well as
between technologies and according to how the test is
applied (e.g., sample number) and what is chosen as the
cutoff.
Generalizations about performance accuracy are com-
plicated by test use in different populations and in different
ways. This in particular pertains to the cutoff for positivity
and the number of fecal samples collected. It is readily
apparent from Figs. 3 and 4 that FITs are able to achieve a
Fig. 3 Reported sensitivity and specificity for CRC of a range of
gFOBT [47–58]
Fig. 4 Reported sensitivity and specificity for CRC of a range of FIT
[38, 39, 48, 54, 55, 59–66]
Table 2 Comparison of two gFOBT and one FIT in a screening
population (n [ 8,000) in California [22]
Hemoccult II
(%)
Hemoccult
sensa (%)
HemeSelect
(%)
Sensitivity for CRC 37.0 79.0 69.0
Proportion of
positive tests
2.5 13.6 5.9
Specificity for
cancer
98.0 87.0 94.0
PPV for cancer 6.6 2.5 5.0
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higher sensitivity for cancer and show a tighter curvilinear
relationship between sensitivity and specificity than
gFOBT. From Fig. 4, it is also apparent that FITs provide a
broad range of options for matching each of the Scenarios
1–3 (see Sect. 3).
To more critically match tests to the screening scenarios
described above, three main topics will be addressed:
comparison of gFOBT kits, comparison of FIT devices and
systems and comparison of gFOBT with FIT.
Comparison of gFOBT Kits
Results of a large screening study in about 8,000 subjects
are summarized in Table 2 [22]. In this study, the gFOBT
sensitivity for cancer was 37 %, consistent with estimates
from the Nottingham RCT [4]. The same study (Table 2)
showed that sensitivity for cancer doubled to 79 % with a
high-sensitivity gFOBT, but the number of positive tests
increased over fivefold. In other words, detection of twice
as many cancers required more than five times as many
colonoscopies. A subsequent study by the same group [67]
returned a positivity rate of 10.1 % and a sensitivity for
cancer of 64.3 % (CI 35.6–80 %) with the high-sensitivity
gFOBT.
While rehydration of gFOBT increased program sensi-
tivity for cancer in the Minnesota RCT (92.2 % compared
with 80.8 % for nonhydrated), it also decreased specificity
(90.4 % compared with 97.7 %) [1] and resulted in a much
higher test positivity rate. In a separate comparison, the
rehydrated gFOBT had a positivity rate more than two
times higher than a sensitive gFOBT (15 vs 7 %), but a
lower PPV (2.6 vs 4.9 %) [68].
These findings, taken together with the specificity
problems described above in Sect. 1.3.1 for gFOBT, make
it clear that ‘‘high-sensitivity’’ gFOBTs detect approxi-
mately twice as many cancers compared with nonhydrated
gFOBT but at a marked deterioration in specificity and
increase in test positivity rate. Furthermore, the increase
seems greater with rehydration and is unpredictably high in
some populations such as in certain Asian populations [24].
We would therefore conclude that traditional gFOBT
can be suitable for Scenario 1 screening settings (limited
colonoscopy resources) but not for Scenario 2 (maximum
sensitivity required). To further meet the demands of
Scenario 1, and increase PPV and reduce the number
needed to colonoscope, some programs (e.g., Scotland,
England) further restrain the test positivity rate and
colonoscopy referral by requiring that at least 5 of 6 win-
dows (using a three-sample gFOBT that has two windows
per sample card) need to be positive on initial screening.
Those with 1–4 positive panels are then subject to some
form of retesting [69]. High-sensitivity gFOBTs are better
suited for Scenario 2, although rehydration is not a desir-
able way to achieve this and should be abandoned.
Comparison of FIT Devices and Systems
A limited number of studies have compared FIT devices
and systems. There are many qualitative products available
[40] plus a smaller, but growing, number of quantitative
devices. These studies have varied in size, devices tested,
methods and outcomes reported, all of which make com-
parison between studies challenging. As a consequence, a
call has been made for standardized reporting of FIT [29,
70, 71].
FIT sensitivity and specificity are shown from 13 studies
in Fig. 3. They show the expected curvilinear relationship
between sensitivity and specificity and demonstrate that
one can readily choose a FIT with high sensitivity for CRC
(at the cost of reduced specificity) or one with high spec-
ificity and hence constrained test positivity rate yet still
achieving a cancer sensitivity above 50 %.
It is rare for a screening program using FIT to require
more than 1 or 2 fecal samples [40]. Several studies have
indicated that two samples give the best sensitivity and
specificity for cancer [55, 63], with one study showing no
difference in sensitivity between 2 and 3 samples and no
difference in specificity between one and two samples [63].
Another study showed that offering 1 or 2 FITs did not
affect uptake [72]. Positivity is higher with multiple sam-
ples collected, and this has been achieved without mark-
edly increasing the number of colonoscopies needed to
detect a neoplasm [64] although this would be dependent
on the cutoff used.
As indicated above in Sect. 2.2.1, if one chooses a
quantitative FIT, then the cutoff can be chosen to suit the
screening scenario. The trade-offs are well described by
Rozen et al. [64]. Sensitivity is lowest and positivity
highest when a low hemoglobin concentration is chosen for
the cutoff, while specificity and positive predictive value
are highest at a high concentration. Rozen et al. [64] found
that a 95 % specificity for CRC (considered appropriate for
average-risk screening) was achieved with a one-sample
quantitative FIT with a 100 ng/mL cutoff of hemoglobin in
sample buffer (equivalent to 20 lg Hb/g feces with an OC
Sensor FIT), whereas two or three samples at 50 ng/mL
(10 lg Hb/g feces with OC Sensor) cutoff increased sen-
sitivity but decreased specificity to 90.2–87.8 % and
increased colonoscopy workload. Similar studies in other
populations do not return the same values, and when
choosing a test for screening, a test’s operating character-
istics need determination in the intended target population.
Nonetheless, FITs are highly flexible and can be used into
Scenarios 1, 2 or 3!
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Comparison of gFOBT and FIT
A number of studies have compared gFOBT with FIT, with
the same limitations applying (see Sect. 3.1.2) when
comparing different FITs. Because of the broad choice of
FITs and the broad range of performance characteristics
(Fig. 4), one must be guarded when making generalizations
especially when using a quantitative FIT since the operat-
ing characteristics are not fixed and can be easily adjusted
to suit the screening scenario.
Higher sensitivities are achievable for CRC with FIT
than gFOBT. For example, one test with a positivity
threshold of 20 lg Hb/g feces as cutoff has been reported
to have a sensitivity for cancer of 87.1–92.3 % compared
with 30.8–74.2 % for a traditional gFOBT [54, 55]. These
recent results mirror an early large-scale comparison as
shown in Table 2 when an early FIT was compared to a
traditional gFOBT.
Specificity is generally reported to be slightly lower with
FIT compared with a traditional gFOBT. For example, a
commonly used FIT at a fecal hemoglobin cutoff of 20 lg
Hb/g feces has a specificity of 90.1–94.2 % compared with
92.4–95.7 % for a traditional gFOBT [54, 55]. However, if
a quantitative FIT is used and the cutoff is set at a level that
returns the same test positivity rate as the gFOBT under
comparison, the PPV for cancer is higher with the FIT than
with the gFOBT [48, 73].
A specificity advantage for FIT is the higher sensitivity
for cancer when used at low cutoff. As shown in Table 2, a
FIT returned a sensitivity for cancer comparable to that of a
high-sensitivity FOBT but less than half the test positivity
rate—this means the number needed to colonoscope to
detect each cancer was much lower.
Test positivity rate in a general screening population
tends to be higher with FIT compared with gFOBT. One
comparison using a FIT at a positivity threshold of 20 lg
Hb/g feces (and collection of 1 sample), the positivity rate
for the FIT was 3.4–5.5 % compared with 2.4–3.5 % for
the gFOBT [37, 74, 75]. Despite this, the PPV for cancer
was similar; 8.6–10.2 % for FIT compared with
9.7–10.7 % for a gFOBT [37, 75]. This means that, in
practice, more cancers are detected by FIT but not at a
significantly higher rate of colonoscopies done per cancer
detected.
FITs are more sensitive for advanced adenomas than
gFOBT and so improve capacity to prevent cancer. Several
studies show that FIT has a sensitivity for advanced ade-
noma 2–3 times that of gFOBT although this is dependent
on the chosen cutoff concentration [48, 54, 55].
Based on these findings, FITs are clearly the optimal
technology for Scenarios 2 and 3. For Scenario 1, the
advantage over gFOBT is not quite so marked and given
that FITs generally cost a few dollars more than gFOBT, a
case for retaining gFOBT in Scenario 1 can sometimes be
sustained, although the issue of population participation
needs consideration (see Sect. 3.3 below).
Finally, the flexibility of quantitative FIT enables
‘‘smarter’’ use of FIT, including first-round screening
undertaken with a more sensitive configuration (low cutoff,
use of two samples) followed by subsequent rounds with
less sensitive configuration based on the knowledge that a
proportion of prevalent lesions will have been removed.
Causes of Test Positivity
A number of factors other than the test configuration itself
can contribute to the variability in FIT positivity reported
by different screening programs. The basis for these dif-
ferences is that positivity rate is directly related to the
tested population. It is known that positive tests occur more
frequently in men than in women, in older populations and
in the more economically disadvantaged [72, 75–80]. The
distributions of fecal hemoglobin concentration are differ-
ent from country to country [81]. Previous participation in
FIT screening [82] also influences positivity rate. The role
of other factors in affecting the FIT positivity rate is not so
thoroughly explored. Time between sampling and test
development had no significant effect in one study [72].
Other studies do suggest the possibility of degradation of
hemoglobin with delayed sample return [83, 84].
Ambient temperature may affect FOBT positivity as
in vitro studies show that hemoglobin levels in samples fall
at temperatures above 20 C [85, 86], most likely due to
degradation. This is confirmed in population screening
programs, with most studies finding that the summer
months are significantly associated with a decrease in the
positivity rate for both FIT [72, 87, 88] and gFOBT [89–
91]. Taking the former studies into consideration, the
Australian National Bowel Cancer Screening Program now
avoids sending FITs to participants during summer [80].
Additional nonneoplastic factors reported to affect FIT
positivity include
• Medication: use of anti-platelet drugs increases posi-
tivity rate [59]
• First versus repeated participation; positivity rates are
higher in first-time participants
• Personal history: positive result was more likely in
those who had a personal history of colorectal neoplasia
[92]
• Benign bleeding disorders increase positivity rate
These variables are likely to differ between populations
and are uncommonly fully documented in reports on pop-
ulation screening studies. The call for standardized
reporting of studies using FOBT should facilitate an
understanding of the differences between studies.
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Behavioral Considerations
It is over a decade now since it was shown that mass,
impersonal population screening with FOBT achieves better
participation rates when using a FIT relative to gFOBT [25,
93]. RCTs addressing participation as the outcome show that
participation is improved by providing an easier device,
restricting the need for fecal sampling to only one or two
bowel movements, and removing the need to restrict diet
and certain drugs [25, 93]. An early 2-sample brush FIT
achieved 67 % better participation than a 3-sample stick-
sampling gFOBT with dietary restrictions [93]. Subsequent
studies confirm better participation with FIT [37, 75, 94, 95]
even when populations differ in the effect of other deter-
minants of participation such as socioeconomic status,
gender, age, nature of the diet and hence impact of dietary
restrictions. Moreover, using a FIT compared to a traditional
gFOBT increases participation especially in the young,
males and the deprived, the very groups that have low par-
ticipation with traditional gFOBT [96].
At the population level, participation is crucial to detec-
tion of neoplasia since the rate of cancer detection in the
population is the product of sensitivity for cancer and the
participation rate [17]. In other words, behavioral parameters
are just as important as technical performance when con-
sidering what test achieves the desired cancer detection rate.
In conclusion, population participation is consistently
higher with FIT than gFOBT which addresses the
requirements of Scenario 4.
Laboratory and Regulatory Considerations
The advantages of FIT over gFOBT in the laboratory are
outlined in Sect. 2.2.1. Traditionally, FOBTs have been
seen in many countries as point-of-care (POC) tests with a
history that goes back 3–4 decades. In the POC test format,
they have generally escaped attention in the increasingly
stringent quality assurance processes that now apply to
diagnostic laboratories around the world [71]. This is
despite the well-documented issues with gFOBT readabil-
ity [31]. Efforts are underway in some countries to address
this, but many still underrate the importance of paying
careful attention to test QA. In practice, QA of both FIT
and gFOBT requires attention to both consistency of
sample collection and analytical performance. Good QA
procedures for sample collection are difficult for both
gFOBT and FIT. Analytical QA procedures are also diffi-
cult for gFOBT but not for quantitative FIT where standard
internal QC and external QA procedures can be easily
adopted. There has been a recent call to standardize
reporting of studies on FOBT, especially those including
FIT, by using the FITTER criteria [29]. Inherent in these is
the inclusion of total quality management strategies.
There is considerable variation between countries con-
cerning FOBT approval for marketing and reimbursement.
Where approval processes consider FOBT as just POC
tests, the evidentiary standards to register a new test are
often not high. Quantitative FITs, especially where there is
a degree of automation, are not POC tests and should be
regulated as appropriate for general laboratory-based tests.
Flexibility with Quantitative Tests
When implementing screening with FOBT, flexibility can
be achieved in a number of ways. Programmatic perfor-
mance characteristics of both gFOBT and FIT can be
manipulated to some degree by altering the screening
interval (e.g., annual, biennial or triennial), the number of
fecal samples collected and the number of gFOBT ‘‘win-
dows’’ required to be positive to trigger colonoscopy.
However, the greatest degree of flexibility is provided by
quantitative FIT as outlined in Sect. 2.2.1 and shown in Fig. 2.
Thus, a quantitative FIT can be used in any of the screening
program scenarios described in Sect. 3. The desired balance
between detection and the effort involved in detection (i.e., the
workload) needs to be decided, and in a face-to-face consul-
tative setting, this decision needs to be tailored to the
requirements of the individual. Once the prime scenario for
screening is decided, the test operating characteristics (see
Table 1) need to be selected to match the chosen scenario.
Two examples explain how this can work. For instance,
if one wishes to control colonoscopy workload to a specific
proportion of participants (Scenarios 1 or 3), then one
would choose a cutoff concentration that returns the cor-
responding test positivity rate in the target population [97].
While guidance can be obtained from studies undertaken
by others, pilot studies in the intended context are needed
to verify this choice. It becomes easier with a quantitative
test to adjust the cutoff if the outcome is as required, a
qualitative test would necessitate selection of a different
test product involving a further pilot study.
If the choice is to maximize detection (Scenario 2), then
a cutoff that gives the desired sensitivity can be chosen. It
can be seen from Figs. 3 and 4 that in addressing Scenario
2 (which aims at high detection) this is generally achieved
with a sensitivity that corresponds to a specificity of 90 %
or worse. It would seem wise to use a FIT even in that
setting since the colonoscopy workload will be less for the
same benefit in detection.
Intention-to-Screen Outcomes with FIT and gFOBT
A few programs have compared gFOBT and FIT on an
intention-to-screen basis, where behavioral and accuracy
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characteristics interact to determine detection of neoplasia
and the burden of detection within the population.
The first such paper, from The Netherlands [75], showed
that improved sensitivity and participation rates with a FIT
compared with a gFOBT led to doubling of the detection of
cases with advanced adenoma or cancer in a large study.
While this additional detection required approximately
double the number of colonoscopies, the number of colo-
noscopies per significant neoplasia case detection was
approximately the same. In other words, the extra effort
associated with the FIT seemed justified.
Hol et al. [37] reported a similar study comparing
gFOBT, FIT and sigmoidoscopy. The results were similar.
Participation rates were 49.5 and 61.5 %, respectively, for
gFOBT and FIT with positivity rates of 2.8 and 4.8 %,
respectively. Cancers were detected in 0.3 % and 0.5 %
and advanced adenomas in 0.9 and 2.0 %, respectively,
while PPV of each test did not differ.
Considering the combined advantages of improved
participation and improved detection, and given that FIT
exploits the same biological basis for early detection as
gFOBT, FIT must be considered superior to gFOBT for
CRC screening.
Challenges and Controversies
There are several aspects of FOBT usage that warrant
particular consideration.
The first concerns the number of fecal samples. While
three samples are the norm for gFOBT, FITs return equiv-
alent or better performance with just one or two samples.
Increasing the number, and referring to colonoscopy as soon
as at least one sample tests positive, does improve sensitivity
[55, 63, 73, 98] but also usually leads to a reduction in
specificity [63, 73, 98]. In contrast, 2-FIT testing with
referral only if both tests are positive decreases sensitivity,
but increases specificity. Participation is likely similar to 1-
and 2-sample FIT. The few studies that have addressed this
show no or only a marginal difference [98]. It should be
noted that costs will be reduced if one sample is used [99].
If using quantitative FIT, it is possible to independently
vary sample number and cutoff for positivity [55, 73, 100].
As a consequence, if using the a quantitative FIT, programs
tend to choose a cutoff of 10–30 lg Hb/g feces when
testing one sample compared with 20–40 lg Hb/g feces
when testing two samples. For cancer detection, there is
little difference between these options, but it has been
pointed out that adenoma detection is better when two
samples are tested [100]. It should be stressed that these
results concern single, first-round screening only. With
repeated rounds, the yields of 1- and 2-FIT testing are
likely to approximate.
The second issue is the cutoff to be used. It should be
obvious from the discussions above that this depends on
choice of screening scenario. FOBT result identifies the
likelihood that cancer is present. In other words, the chosen
screening scenario supported by pilot studies in the target
population will identify the most suitable cutoff.
The third issue is whether any role remains at all for
gFOBT. We would argue that when a high-sensitivity
FOBT is desired (as for Scenarios 2 or 3), FITs provide
similar sensitivity without the colonoscopy workload
required with gFOBT. There might be a case for use of
traditional gFOBT for Scenario 1 but only if one disregards
the major disadvantages of gFOBT and the behavioral and
laboratory advantages of FIT. There is a small cost dif-
ferential, but this proves insignificant in cost-effectiveness
studies [101].
The fourth issue is the screening interval. While one
might speculate based on theory and modeling, that higher-
sensitivity tests might be repeated at longer intervals,
without precise knowledge of the ideal length of time in
which a cancer is detectable by FIT and remains highly
curable, it is impossible to predict whether the interval can
be extended beyond second yearly. One study that con-
sidered this and compared 1-, 2- and 3-year intervals found
similar yield in the second round of low cutoff FIT [102].
Modeling of further data from different studies will help to
determine the optimal approach for individual populations
based on their characteristics and resources.
A fifth issue is whether we should always use the same
cutoff value for fecal hemoglobin concentration in a pro-
gram, no matter who is being screened and whether this is
the first round of screening or a subsequent round. At this
point, there is no direct evidence and modeling the many
possibilities is not fully developed. There is a case for an
initial screen using a very sensitive FOBT, with subsequent
screens using adjusted cutoffs so as to achieve a desired
sensitivity, colonoscopy workload or efficiency of detec-
tion. More data to assist such modeling are required and
such can only be achieved with quantitative FIT.
A complementary issue is whether different cutoffs
should be used for different subpopulations. Since fecal
hemoglobin concentrations are related to age, gender and
deprivation, and such data are usually obtainable for invi-
tees, cutoffs could be adjusted so as to achieve a desired
sensitivity, colonoscopy workload or efficiency of detec-
tion within a subgroup. One might even take this further to
the individual level and use more complex risk algorithms
as briefly discussed earlier [103].
Another issue is quality control of FOBT and whether
screening programs using FIT should use automated FIT
(where the test is measured and interpreted by a comput-
erized analytical instrument) or POC tests (where the test is
generally undertaken by personnel inexperienced in
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analytical procedures including QA). It is concerning that
93 % of the FITs in the US are POC and there is no
oversight of quality control [35].
Finally, in the selection of a FIT product, should only
those FIT with demonstrable quality control and screening
outcome performance be adopted over those with little or no
supporting evidence? Guidelines usually refer to FOBT in a
generic manner, whereas very few brands have adequate
supporting data to substantiate their use. It would be valu-
able to specify what criteria are needed before a test is
approved for use. This is often sought when providers set up
a process of procurement of FOBT. Guidance on what
should be requested has been published [Quantitative FIT
Procurement. FIT for Screening Expert Working Group,
Colorectal Cancer Screening Committee, World Endoscopy
Organization. Available http://www.worldendo.org/assets/
downloads/pdf/activities/weo_expert_working_group_fit_
discussion_doc_no6_pr.pdf.]
Summary/Conclusions
The choice of FOBT should suit the requirements of the
screening setting so that it can achieve the desired balance
between detection and the effort involved in detection as
well as the desired the degree of screening participation.
The following summarizes how FOBTs best suit each of
the four main strategic scenarios:
1. Highly constrained colonoscopy resources: use an
FOBT with a low test positivity rate in the target
population. While this can be achieved with either
certain gFOBT or FIT, FITs are overwhelmingly
preferable.
2. Maximum detection: For gFOBT, high-sensitivity
gFOBT might be considered suitable, but FIT can
achieve the same high sensitivity with better specificity
and fewer colonoscopies. Thus, if the goal is maximum
sensitivity, FIT should be the test of choice potentially
using two or more samples. Simply referring to an
FOBT as ‘‘high sensitivity’’ fails to adequately char-
acterize the test, especially as high-sensitivity gFOBTs
are subject to great and unpredictable variations in
performance.
3. Balancing detection and burden of detection: quanti-
tative FITs are ideal for this situation as they provide
flexibility to tailor to the circumstances of either a
population or an individual.
4. Optimizing participation: FITs are superior to gFOBT.
Overall, FIT technology is more selective for colorectal
bleeding, less affected by nonpathological factors such as
diet and drugs, more suitable for the modern laboratory
and large-scale processing of tests, more acceptable to
individuals and more flexible in terms of choice of
screening test characteristics than is the gFOBT technol-
ogy. It has been suggested that gFOBT is now obsolete
[104].
Population screening for CRC should be undertaken
predominately with a well-characterized automated FIT in
an accredited laboratory with trained staff applying rigor-
ous quality assurance procedures. Screening programs need
to be open to regular audit and performance monitoring,
and reported results subject to review and external scrutiny.
POC FITs also need to meet high standards of quality both
before being approved for use and when implemented.
POC FIT should only be used where laboratory-based
analysis is not feasible and then the analytical performance
of the product should be well characterized, a rigorous
training program must be implemented and quality moni-
toring procedures adopted.
Screening guidelines need to recognize these different
scenarios and the end user flexibility that can be gained
with quantitative FIT. Choice of a FOBT should also
consider the available evidence for that test, including test
operating characteristics, subject acceptance and quality
issues that ensure a reliable and robust test. Guidelines
should make these requirements clear and not imply that all
FOBTs are the same.
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